Navigation Links
CVBT Closes Clinical Development Agreement for Coronary Heart Disease Drug Candidate
Date:11/13/2008

LAS VEGAS, Nov. 13 /PRNewswire-FirstCall/ -- CardioVascular BioTherapeutics, Inc. (OTC Bulletin Board: CVBT) (the "Company") has entered into its first clinical development agreement for its Coronary Heart Disease drug candidate with Cardio Neo-Genesis, LP ("CNG"). The agreement, dated November 11, 2008 states that CNG can fund up to $15,000,000 of the clinical development for the Company's Coronary Heart Disease (CHD) drug candidate. The agreement also provides for a royalty to CNG payable from 5% of CVBT's cash-flow stream on its CHD drug up to 20 times return to CNG's limited partners.

"CVBT is currently utilizing clinical development agreements to fund and advance our drug development candidates," according to Mr. Mickael A. Flaa, CVBT's Chief Financial Officer. Mr. Flaa continued, "Given the stress in the financial markets at this time, we looked to the lessons of history for a strategy to finance CVBT's drug development program. The clinical development arrangements that CVBT has entered into are similar in structure to those used successfully by Amgen, Genentech, Biogen, and others over 20 years ago to fund their drug development programs."

"This development agreement is a positive step in advancing CVBT's CHD drug candidate given today's financial markets," said Mr. Daniel C. Montano, CVBT's CEO. Mr. Montano continued, "I believe that CVBT's existing shareholders will benefit from this new source of funding which does not permanently dilute their shareholdings."

About CardioVascular BioTherapeutics

CVBT (OTCBB: CVBT) is a biopharmaceutical company developing human FGF-1 for cardiovascular diseases characterized by inadequate blood flow to a tissue or organ. In addition to the Phase II trial it is conducting in patients with severe coronary heart disease, the company has two FDA-authorized clinical trials in the areas of impaired wound healing seen in diabetics and in patients suffering from peripheral artery disease of the
'/>"/>

SOURCE CardioVascular BioTherapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2

Related biology technology :

1. OncoVista, Inc. Closes on $6.8 Million Financing and Acquires Control of a Public Shell Company
2. Genmab Discloses Target and Development Plans for HuMax-Inflam
3. Oxford Finance Corporation Closes $7 Million Debt Facility with Othera Pharmaceuticals
4. RoundTable Healthcare Partners Closes Sale of MedAssist Holding, Inc. to Firstsource Solutions Limited
5. Gilde Healthcare Partners Closes EUR 150 Million European Healthcare Venture Fund
6. Symmetry Medical Discloses Accounting Issues at Sheffield, UK Operating Unit and Possible Restatement
7. BioVex Closes Second Round of Series E Financing
8. Pharmaxis Closes Share Purchase Plan
9. The closest look ever at native human tissue
10. Helix BioPharma closes $16.9 million private placement of common shares
11. Senesco Technologies Closes on Additional $4.0 Million of Previously Announced Financing

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/9/2009)...ia/ -- The pharma and biotech sectors are,at a piv...facing significant,pressure to change with thinnin...,lower prices and a greater regulatory burden, the...ave made the work of creating new drugs harder tha...ced to globalize their R&D,operations, especia...
(Date:11/9/2009)... is a research industry first, allowing veterinary...ch safety study data to be managed in one software...lls, NJ (PRWEB) November 9, 2009 -- Xybion Medical...tima™ VM, an integrated enterprise software ...e and care of veterinary research subjects. Pristi...
(Date:11/7/2009)...re/ -- Research projects in the areas of mathemati... as Tim Kunisky of Livingston, NJ and the team of ...received the highest honors at the Region Five Fin...ce & Technology, the nation,s premier high sch...om.com/cgi-bin/prnh/20070904/SIEMENSLOGO ) ,,...
(Date:11/6/2009)...-- Myriant Technologies LLC ("Myriant"), a private...newable bio-chemicals, Uhde Corporation of America...one of the world,s leading engineering contractors...ngineering, procurement & construction (EPC) o... renewable feedstocks. The execution of this alli...
Breaking Biology Technology:Pharma and Biotech Leaders to Converge in Shanghai 2Xybion Unveils Pristima™ VM, an Integrated Enterprise Software Solution for Vivarium and Veterinary Care Management 2Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 2Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 3Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 4Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 5Mathematics and Biochemistry Research Earn Top Prize at Nation's Premier High School Science Competition 6Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 2Myriant Technologies LLC, Uhde Corporation of America and Uhde GmbH Announce Alliance for Engineering, Procurement & Construction of World Scale Renewable Succinic Acid Plants 3
... Calif., July 31 Alsius Corporation,(Nasdaq: ALU...ture,management (IVTM(TM)) therapies for criticall...a conference call to discuss the Company,s,second ...ll Worthen,president and CEO, will host the call b...ern Time) on Thursday, August 7. A press release f...
... Colo., July 31 Sierra Neuropharmaceuticals,Inc.,...-brain treatment of,neurological diseases, announc...ing. Co-leads in the funding were HealthCare Ventu...tners. Other investors include High Country,Ventur...etary drug development process that makes use of,s...
...OWN, Pa., July 31 The Quigley,Corporation (Nasdaq...,operations of $2.1 million, for the second quarte...orted for the second quarter ended June 30,2007. F...ere $7.4 million,compared to $8.4 million reported...t sales were influenced by distribution changes an...
Other Biology Technology:Alsius Corporation to Host Second Quarter 2008 Financial Results Conference Call on August 7 2Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 2Sierra Neuropharmaceuticals Completes $21.5-Million Series A Funding Round 3The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 2The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 3The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 4The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 5The Quigley Corporation Reports Second Quarter 2008 Results: Continues Investment in Pharmaceutical R&D Future 6
(Date:11/9/2009)... Naturwissenschaften is publishing a special issu...ology" to commemorate Darwin,s On the Origin of Sp...r 1859. Guest editor and author of the lead articl...iology and evolutionary biology at the University ... issue are available free of charge until 30 Decem...
(Date:11/9/2009)..., November 09, 2009 / b3c newswire / - Today, T...venth Wave, an American organization for contract ...ies have signed a letter of intent with regard to ...M. The letter of intent proposes a collaboration i...or commercialization in North America. The TIM sys...
(Date:11/8/2009)...d. - Researchers at Purdue University have discove...ers in spinal cord injuries using nano-spheres tha...n accident. , The synthetic "copolymer micelles"...diameter, or roughly 100 times smaller than the di...een studying how to deliver drugs for cancer treat...
Breaking Biology News(10 mins):TNO and Seventh Wave sign letter of intent on joint preclinical pharmaceutical outsourcing services 2Findings show nanomedicine promising for treating spinal cord injuries 2Findings show nanomedicine promising for treating spinal cord injuries 3AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 1AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 2AcelRx Announces Perfect Performance of Handheld Component of ARX 01 Sufentanil NanoTab PCA System in a Phase 2 Study 52359 3Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 1Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 2Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 3Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 4Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 5Human Genome Sciences Announces New Order for Raxibacumab 28ABthrax 28TM 29 29 from U S Government 13137 6Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28 2009 13135 1Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2009 Financial Results on July 28 2009 13135 2
... nutritious and tasty, but don’t count on them to ...er Epidemiology, Biomarkers & Prevention, rese... Fred Hutchinson Cancer Research Center report tha...tomatoes, does not effectively prevent prostate ca...on between beta-carotene, an antioxidant related t...
... Universitat Autònoma de Barcelona (UAB), in coope...-chemical biosensor which detects the presence, in...he most widely used herbicides in agriculture and ...vironment- as well as antibiotics in food. The bio...the expensive laboratory methods which are used to...
...ar symmetrical at first glance, but we,re full of ... up a pencil or throw a baseball, to where languag... our internal organs, humans are a glut of asymmet...norhabditis elegans has nerves on its left and rig...ndedness, the determination of which nerves develo...
Other Biology News:No magic tomato? Study breaks link between lycopene and prostate cancer prevention 2A new portable biosensor detects traces of contaminants in food more quickly and cheaply 2Left-right wiring determined by neural communication in the embryonic worm 2
Rabbit Anti-NF-kB p65, phospho (Ser345) Antibody, Unconjugated from Spring Bioscience
Rabbit Anti-Human ADAMTS-4, disintegrin-like domain Antibody, Unconjugated from CHEMICON
Rabbit Anti-Streptococcus Enterotoxin C Polyclonal Antibody, Unconjugated from Abcam
... immunocapture up to 50 g of Complex V from heart ...rt mitochondria for control immunocapture. The Com...TP synthase complex (E.C. 3.6.3.14) from small amo...is of assembly state and activity. Thus the enzyme...
Biology Products: